Rhythm Pharmaceuticals’ (RYTM) Buy Rating Reiterated at Needham & Company LLC
Needham & Company LLC reissued their buy rating on shares of Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) in a report issued on Wednesday,Benzinga reports. They currently have a $64.00 price objective on the stock. Other equities research analysts have also recently issued reports about the stock. Oppenheimer assumed coverage on shares of Rhythm Pharmaceuticals in […]
Needham & Company LLC reissued their buy rating on shares of Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) in a report issued on Wednesday,Benzinga reports. They currently have a $64.00 price objective on the stock. Other equities research analysts have also recently issued reports about the stock. Oppenheimer assumed coverage on shares of Rhythm Pharmaceuticals in […]
